References
- Baselt, R. C. 2002. Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications.
- Dern, L. 2016. Codeine therapy and CYP2D6 genotype. Medical Genetics Summaries (Internet). http://www.ncbi.nlm.nih.gov/books/NBK100662/ ( accessed June 11, 2016).
- Ewald, A. H., and H. H. Maurer. 2008. 2,5-dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicology Letters 183 (1–3):52–57. doi:10.1016/j.toxlet.2008.09.014.
- Midha, K. K., K. Bailey, J. K. Cooper, and J. W. Hubbard. 1979. Metabolic O-demethylation of 3,4-dimethoxyamphetamine in vivo in dog and monkey. Xenobiotica 9 (8):485–90. doi:10.3109/00498257909087262.
- Pizarro, N., M. Farré, M. Pujadas, Peiró, A. M., Roset, P. N., Joglar, J., and de la Torre, R. 2004. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metabolism and Disposition: The Biological Fate of Drugs 32 (9):1001–07.
- Schneir, A., B. T. Ly, K. Casagrande, M. Darracq, S. R. Offerman, S. Thornton, C. Smollin, R. Vohra, C. Rangun, C. Tomaszewski, and R. R. Gerona. 2014. Comprehensive analysis of “bath salts” purchased from California stores and the Internet. Clinical Toxicology 52 (7):651–58. doi:10.3109/15563650.2014.933231.
- Shulgin, A. 1976. Psychotomimetic agents. In Psychoph-armacologic agents, ed. E. M. Gordon, Vol. 4, 96–99. New York, NY: Academic Press.
- Shulgin, A., and A. Shulgin. 1991. PiHKAL: A chemical love story. Lafayette, CA: Transform Press.
- Test Result Statistics: Summary Data. n.d. http://www.ecstasydata.org/stats.php?row=Summary&percent=1. ( Accessed April 22, 2016).
- United Nations Office of Drugs and Crime (UNODC). 2015. World Drug Report 2015. United Nations Office on Drugs and Crime. New York, NY: United Nations.